Epix Looks To Late-2008 Approval For Vasovist Following NDA Resubmission
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA was filed again June 30 including a re-read of images from a previously conducted clinical trial.
You may also be interested in...
Epix Seeks Partner To Market Vasovist
After a five-year ordeal, the firm gets FDA OK for the cardiovascular contrast agent.
Epix Seeks Partner To Market Vasovist
After a five-year ordeal, the firm gets FDA OK for the cardiovascular contrast agent.
Epix Seeks New Vasovist Partner After Bayer Backs Out
Focus on competing Magnevist could have prompted Bayer Schering’s decision.